XML 43 R19.htm IDEA: XBRL DOCUMENT

Segment Information and Concentration of Business Risk (Tables)

3 Months Ended

Mar. 31, 2015

Segment Information and Concentration of Business Risk [Abstract]

The following is our segment information for the three months ended March 31, 2015 (in thousands).

	Isis Core				Akcea Therapeutics				Total

Revenue:
Research and development		$	61,892			$	—			$	61,892
Licensing and royalty			691				—				691
Total segment revenue		$	62,583			$	—			$	62,583
Loss from operations		$	(2,232	)		$	(7,098	)		$	(9,330	)

Schedule of revenue from significant partners

We have historically funded our operations from collaborations with corporate partners and a relatively small number of partners have accounted for a significant percentage of our revenue. Revenue from significant partners, which is defined as ten percent or more of our total revenue, was as follows:

	Three Months Ended March 31,
	2015		2014
Partner A		63%		36%
Partner B		26%		12%
Partner C		1%		12%
Partner D		0%		27%

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References+ Details

- Definition

Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.

+ References+ Details